Oliver Engert Purchases 2,660 Shares of Enovis (NYSE:ENOV) Stock

Key Points

• Enovis insider Oliver Engert purchased 2,660 shares at an average price of $18.80, investing $50,008 and increasing his holdings to 63,898 shares. He also made several additional purchases in September and June.
• Enovis shares traded at $19.95, near the company’s 12-month low of $18.52, while the stock carried a $1.15 billion market capitalization. The company recently beat quarterly earnings expectations, reporting $0.90 in EPS versus the $0.85 consensus and revenue of $582.78 million.
• Wall Street maintains a “Moderate Buy” consensus on Enovis, with 10 Buy, one Hold, and one Sell rating and an average price target of $40.38. Institutional investors own approximately 98.45% of the company’s shares.

Enovis Corporation (NYSE:ENOV - Get Free Report) insider Oliver Engert acquired 2,660 shares of the business's stock in a transaction on Friday, September 4th. The stock was acquired at an average price of $18.80 per share, with a total value of $50,008.00. Following the transaction, the insider owned 63,898 shares in the company, valued at approximately $1,201,282.40. The trade was a 4.34% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Oliver Engert also recently made the following trade(s):

• On Wednesday, September 2nd, Oliver Engert bought 2,458 shares of Enovis stock. The shares were acquired at an average price of $20.32 per share, for a total transaction of $49,946.56.
• On Thursday, September 3rd, Oliver Engert bought 5,140 shares of Enovis stock. The stock was acquired at an average price of $19.46 per share, with a total value of $100,024.40.
• On Monday, June 15th, Oliver Engert purchased 1,000 shares of Enovis stock. The stock was acquired at an average cost of $20.92 per share, with a total value of $20,920.00.
• On Thursday, June 11th, Oliver Engert purchased 1,200 shares of Enovis stock. The shares were bought at an average price of $21.62 per share, for a total transaction of $25,944.00.
• On Wednesday, June 10th, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were bought at an average price of $23.00 per share, for a total transaction of $23,000.00.

Enovis Price Performance

NYSE:ENOV traded up $1.39 during mid-day trading on Tuesday, reaching $19.95. 3,742,680 shares of the company were exchanged, compared to its average volume of 1,103,625. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. The stock has a market cap of $1.15 billion, a PE ratio of -1.04 and a beta of 1.31. Enovis Corporation has a 12 month low of $18.52 and a 12 month high of $34.28. The company has a fifty day moving average of $25.42 and a 200 day moving average of $24.18.

Enovis (NYSE:ENOV - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping analysts' consensus estimates of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The company had revenue of $582.78 million during the quarter, compared to the consensus estimate of $581.84 million. During the same period in the previous year, the firm posted $0.79 earnings per share. The company's revenue was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts anticipate that Enovis Corporation will post 3.15 EPS for the current fiscal year.

Institutional Trading of Enovis

Several institutional investors and hedge funds have recently made changes to their positions in ENOV. Arax Advisory Partners bought a new position in shares of Enovis in the 4th quarter worth $29,000. EverSource Wealth Advisors LLC increased its holdings in Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company's stock valued at $40,000 after purchasing an additional 707 shares during the last quarter. Allworth Financial LP bought a new stake in Enovis in the second quarter valued at about $36,000. Danske Bank A S acquired a new position in Enovis in the third quarter valued at about $64,000. Finally, Public Employees Retirement System of Ohio acquired a new position in Enovis in the second quarter valued at about $48,000. Institutional investors own 98.45% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ENOV. Evercore set a $32.00 price objective on Enovis in a research report on Monday, July 6th. BTIG Research dropped their target price on Enovis from $40.00 to $36.00 and set a "buy" rating for the company in a research report on Tuesday, September 1st. Zacks Research raised Enovis from a "strong sell" rating to a "hold" rating in a research note on Wednesday, July 29th. UBS Group reiterated a "buy" rating and issued a $51.00 price objective (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. Finally, Canaccord Genuity Group dropped their price objective on Enovis from $50.00 to $45.00 and set a "buy" rating for the company in a report on Monday, August 17th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $40.38.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.